Keratosis

Summary

Keratosis (MONDO:0006566) is a disease (an umbrella term covering 9 Mondo subtypes) and 15 clinical trials. Top therapeutic interventions include imiquimod, ingenol mebutate, and tirbanibulin. A subtype of skin disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 9 Mondo subtypes
• Clinical trials: 15

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	keratosis
Mondo ID	MONDO:0006566
EFO	EFO:1000720
MeSH	D007642
DOID	DOID:161
NCIT	C34745
SNOMED CT	254666005
UMLS	C0022593
MedGen	9625
Anatomy (UBERON)	UBERON:0002027
Is cancer (heuristic)	no

Also known as: keratoderma

Disease family

This is a subtype of skin disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › keratosis

Related subtypes (71): dermatitis, cutaneous mucinosis, skin neoplasm, pyoderma, chronic ulcer of skin, systemic sclerosis, sunburn, severe cutaneous adverse reaction, paronychia, Achenbach syndrome, erythema multiforme, erythematosquamous dermatosis, exanthem, facial dermatosis, hand dermatosis, leg dermatosis, lichen disease, lipodystrophy, mongolian spot, reactive cutaneous fibrous lesion, rosacea, scalp dermatosis, sebaceous gland disorder, skin atrophy, skin sarcoidosis, sweat gland disorder, vesiculobullous skin disease, hyperglobulinemic purpura, ainhum, cheilitis glandularis, erythema palmare hereditarium, multiple benign circumferential skin creases on limbs, actinic prurigo, congenital lethal erythroderma, Parana hard-skin syndrome, Bazex-Dupre-Christol syndrome, nephrogenic systemic fibrosis, erosive pustular dermatosis of the scalp, pseudoxanthoma elasticum-like papillary dermal elastolysis, toxic dermatosis, oral erosive lichen, chronic actinic dermatitis, Jessner lymphocytic infiltration of the skin, acquired kinky hair syndrome, primary cutaneous plasmacytosis, cutaneous pseudolymphoma, corticosteroid-sensitive aseptic abscess syndrome, interstitial granulomatous dermatitis with arthritis, epidermal disease, skin pigmentation disorder, skin vascular disease, Wells syndrome, solar urticaria, pellagra, hereditary epidermal appendage anomaly, keratosis pilaris, dermis disorder, aquagenic pruritus, Boudhina Yedes Khiari syndrome, non-neoplastic nevus, cutaneous sclerosis, pityriasis rotunda, hematohidrosis, skin disorder caused by infection, livedoid vasculopathy, prurigo nodularis, granuloma faciale, sclerema neonatorum, hereditary skin disorder, hand-foot syndrome, Nicolau syndrome

Subtypes (9): keratosis follicularis spinulosa decalvans, acquired keratosis, cholesteatoma, palmoplantar keratosis, porokeratosis, hereditary papulotranslucent acrokeratoderma, acrokeratosis verruciformis, seborrheic keratosis, trichostasis spinulosa

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

4 approved drugs — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Status
Diclofenac	Approved (phase 4)
Fluorouracil	Approved (phase 4)
Imiquimod	Approved (phase 4)
Salicylic Acid	Approved (phase 4)

1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Ingenol Mebutate	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 15.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE4	3
PHASE1	2
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00110682	PHASE4	COMPLETED	Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses
NCT00115154	PHASE4	COMPLETED	Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands
NCT00116649	PHASE4	COMPLETED	Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
NCT07273656	PHASE3	NOT_YET_RECRUITING	Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and Forehead
NCT00239135	PHASE2	COMPLETED	Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel
NCT02813902	PHASE1	WITHDRAWN	A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors
NCT05060237	PHASE1	COMPLETED	Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
NCT00074685	Not specified	COMPLETED	National Registry for Ichthyosis and Related Disorders
NCT00114023	Not specified	COMPLETED	1-Year Follow up to the 1473-IMIQ Study
NCT00121511	Not specified	COMPLETED	The Effect of Efudex Treatment on Photoaged Skin
NCT02737176	Not specified	UNKNOWN	Tobacco Cessation Intervention Study for Oral Diseases
NCT02851693	Not specified	WITHDRAWN	Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection
NCT04336514	Not specified	UNKNOWN	A Longitudinal Quantitative Assessment of the Effectiveness of Metatarsal Pads on Plantar Pressures
NCT05942794	Not specified	UNKNOWN	Identification of Oral Lesions Through an Autofluorescence System
NCT06206681	Not specified	UNKNOWN	Efficacy and Safety of Ultrapulse Carbon Dioxide Laser Treatment in Eyelid Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IMIQUIMOD	4	2
INGENOL MEBUTATE	4	1
TIRBANIBULIN	4	1